This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kagawa, S. Articles by Fang, B. Search for Related Content PubMed PubMed Citation Articles by Kagawa, S. Articles by Fang, B.

Antitumor Activity and Bystander Effects of the Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Gene¹

Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery [S. K., J. G., P. K., J. A. R., B. F.], Department of Veterinary Medicine [L. C. S.], and Department of Surgical Oncology [S. A. C.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310006, China [C. H.]; and Department of Thoracic and Cardiovascular Surgery, The Catholic University of Korea, Seocho-ku, Seoul, 137-340 Korea [S-J. R.]

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been reported to specifically kill malignant cells but to be relatively nontoxic to normal cells. To evaluate the antitumor activity and therapeutic value of the TRAIL gene, we constructed adenoviral vectors expressing the human TRAIL gene and transferred them into malignant cells in vitro and tumors in vivo. The in vitro transfer elicited apoptosis, as demonstrated by the quantification of viable or apoptotic cells and by the analysis of activation of pro-caspase-8 and cleavage of poly(ADP-ribose) polymerase. The intratumoral delivery elicited tumor cell apoptosis and suppressed tumor growth. In comparison with Bax gene treatment, which is toxic to normal cells, TRAIL gene treatment caused no detectable toxicity in cultured normal fibroblasts nor in mouse hepatocytes after systemic gene delivery. Furthermore, coculture of cancer cells expressing TRAIL with those expressing green fluorescent protein (GFP) resulted in apoptosis of both cells, whereas coculture of Bax-expressing cells with GFP-expressing cells resulted in the cell death of the Bax-expressing cells only, which suggested that the transfer of the TRAIL gene resulted in bystander effects. Moreover, culture of cells with medium from TRAIL-expressing cells showed the proapoptotic activity and bystander effect of the TRAIL gene to be not transferable with medium. To further demonstrate the bystander effect of the TRAIL gene, we constructed plasmid vectors encoding GFP-TRAIL or GFP-Bik chimeric proteins. Transfection of the GFP-TRAIL gene into cancer cells resulted in the death of GFP-positive cells and their neighbors, whereas transfection of the GFP-Bik gene killed GFP-positive cells only. Finally, GFP-TRAIL genes, transfected into normal human fibroblasts or bronchial epithelial cells, did not kill such cells, whereas transfected GFP-Bik genes did. Thus, the direct transfer of the TRAIL gene led to selective killing of malignant cells with bystander effect, which suggests that the TRAIL gene could be valuable for treatment for cancers. Together, these results suggest that delivering the TRAIL gene to cancerous cells may be an alternative approach to cancer treatment.

This article has been cited by other articles:

				M. R. Loebinger, A. Eddaoudi, D. Davies, and S. M. Janes Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer Cancer Res., May 15, 2009; 69(10): 4134 - 4142. [Abstract] [Full Text] [PDF]

				L. S. Sasportas, R. Kasmieh, H. Wakimoto, S. Hingtgen, J. A. J. M. van de Water, G. Mohapatra, J. L. Figueiredo, R. L. Martuza, R. Weissleder, and K. Shah Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy PNAS, March 24, 2009; 106(12): 4822 - 4827. [Abstract] [Full Text] [PDF]

				M. Uzzaman, G. Keller, and I. M. Germano In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas Neuro-oncol, January 1, 2009; 11(2): 102 - 108. [Abstract] [Full Text] [PDF]

				S. Hingtgen, X. Ren, E. Terwilliger, M. Classon, R. Weissleder, and K. Shah Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide Mol. Cancer Ther., November 1, 2008; 7(11): 3575 - 3585. [Abstract] [Full Text] [PDF]

				M. M. Shareef, N. Cui, R. Burikhanov, S. Gupta, S. Satishkumar, S. Shajahan, M. Mohiuddin, V. M. Rangnekar, and M. M. Ahmed Role of Tumor Necrosis Factor-{alpha} and TRAIL in High-Dose Radiation Induced Bystander Signaling in Lung Adenocarcinoma Cancer Res., December 15, 2007; 67(24): 11811 - 11820. [Abstract] [Full Text] [PDF]

				M. F. Corsten, R. Miranda, R. Kasmieh, A. M. Krichevsky, R. Weissleder, and K. Shah MicroRNA-21 Knockdown Disrupts Glioma Growth In vivo and Displays Synergistic Cytotoxicity with Neural Precursor Cell Delivered S-TRAIL in Human Gliomas Cancer Res., October 1, 2007; 67(19): 8994 - 9000. [Abstract] [Full Text] [PDF]

				C. Carlo-Stella, C. Lavazza, A. Locatelli, L. Vigano, A. M. Gianni, and L. Gianni Targeting TRAIL Agonistic Receptors for Cancer Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2313 - 2317. [Abstract] [Full Text] [PDF]

				W. Lu, Q. Sun, J. Wan, Z. She, and X.-G. Jiang Cationic Albumin-Conjugated Pegylated Nanoparticles Allow Gene Delivery into Brain Tumors via Intravenous Administration Cancer Res., December 15, 2006; 66(24): 11878 - 11887. [Abstract] [Full Text] [PDF]

				F. Dong, L. Wang, J. J. Davis, W. Hu, L. Zhang, W. Guo, F. Teraishi, L. Ji, and B. Fang Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-{alpha}-Related Apoptosis-Inducing Ligand-Armed Oncolytic Adenovirus Clin. Cancer Res., September 1, 2006; 12(17): 5224 - 5230. [Abstract] [Full Text] [PDF]

				Y. Zhang, J. Gu, L. Zhao, L. He, W. Qian, J. Wang, Y. Wang, Q. Qian, C. Qian, J. Wu, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res., April 15, 2006; 66(8): 4291 - 4298. [Abstract] [Full Text] [PDF]

				S. H. Wang, Z. Cao, J. M. Wolf, M. Van Antwerp, and J. R. Baker Jr. Death Ligand Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Inhibits Experimental Autoimmune Thyroiditis Endocrinology, November 1, 2005; 146(11): 4721 - 4726. [Abstract] [Full Text] [PDF]

				X. Zhang, R. M. Cheung, R. Komaki, B. Fang, and J. Y. Chang Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Non-Small Cell Lung Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6657 - 6668. [Abstract] [Full Text] [PDF]

				R. Shao, D.-F. Lee, Y. Wen, Y. Ding, W. Xia, B. Ping, H. Yagita, B. Spohn, and M.-C. Hung E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation Mol. Cancer Res., April 1, 2005; 3(4): 219 - 226. [Abstract] [Full Text] [PDF]

				J. Shi, D. Zheng, Y. Liu, M. H. Sham, P. Tam, F. Farzaneh, and R. Xu Overexpression of Soluble TRAIL Induces Apoptosis in Human Lung Adenocarcinoma and Inhibits Growth of Tumor Xenografts in Nude Mice Cancer Res., March 1, 2005; 65(5): 1687 - 1692. [Abstract] [Full Text] [PDF]

				D. Jacob, J. Davis, H. Zhu, L. Zhang, F. Teraishi, S. Wu, F. C. Marini III, and B. Fang Suppressing Orthotopic Pancreatic Tumor Growth with a Fiber-Modified Adenovector Expressing the TRAIL Gene from the Human Telomerase Reverse Transcriptase Promoter Clin. Cancer Res., May 15, 2004; 10(10): 3535 - 3541. [Abstract] [Full Text] [PDF]

				D. J. Waxman and P. S. Schwartz Harnessing Apoptosis for Improved Anticancer Gene Therapy Cancer Res., December 15, 2003; 63(24): 8563 - 8572. [Abstract] [Full Text] [PDF]

				R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]

				D. C. J. Spierings, E. G. E. de Vries, W. Timens, H. J. M. Groen, H. M. Boezen, and S. de Jong Expression of TRAIL and TRAIL Death Receptors in Stage III Non-Small Cell Lung Cancer Tumors Clin. Cancer Res., August 1, 2003; 9(9): 3397 - 3405. [Abstract] [Full Text] [PDF]

				S. Armeanu, U. M. Lauer, I. Smirnow, M. Schenk, T. S. Weiss, M. Gregor, and M. Bitzer Adenoviral Gene Transfer of Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Overcomes an Impaired Response of Hepatoma Cells but Causes Severe Apoptosis in Primary Human Hepatocytes Cancer Res., May 15, 2003; 63(10): 2369 - 2372. [Abstract] [Full Text] [PDF]

				J. Guillermet, N. Saint-Laurent, P. Rochaix, O. Cuvillier, T. Levade, A. V. Schally, L. Pradayrol, L. Buscail, C. Susini, and C. Bousquet Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis PNAS, January 7, 2003; 100(1): 155 - 160. [Abstract] [Full Text] [PDF]

				P. S. Schwartz, C.-S. Chen, and D. J. Waxman Enhanced Bystander Cytotoxicity of P450 Gene-directed Enzyme Prodrug Therapy by Expression of the Antiapoptotic Factor p35 Cancer Res., December 1, 2002; 62(23): 6928 - 6937. [Abstract] [Full Text] [PDF]

				T. Lin, J. Gu, L. Zhang, X. Huang, L. C. Stephens, S. A. Curley, and B. Fang Targeted Expression of Green Fluorescent Protein/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Fusion Protein from Human Telomerase Reverse Transcriptase Promoter Elicits Antitumor Activity without Toxic Effects on Primary Human Hepatocytes Cancer Res., July 1, 2002; 62(13): 3620 - 3625. [Abstract] [Full Text] [PDF]

				C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone Apoptosis: Target of Cancer Therapy Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034. [Abstract] [Full Text] [PDF]

				Y. Zou, H. Peng, B. Zhou, Y. Wen, S.-C. Wang, E.-M. Tsai, and M.-C. Hung Systemic Tumor Suppression by the Proapoptotic Gene bik Cancer Res., January 1, 2002; 62(1): 8 - 12. [Abstract] [Full Text] [PDF]